DS
CRL icon

Daniel Sundheim’s Charles River Laboratories CRL Stock Holding History

Daniel Sundheim’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-777,489
Closed -$117M – 38
2025
Q1 		$117M Sell
777,489
-158,331
-17% -$26.5M 1.79% 22
2024
Q4 		$173M Buy
+935,820
New +$180M 2.87% 11

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Daniel Sundheim's CRL Position: Q2 2025 in Review

Daniel Sundheim sold out of Charles River Laboratories (CRL) in Q2 2025, closing a stake of 777,489 shares — an estimated $117M sold.

Daniel Sundheim first reported a position in CRL in Q4 2024 and held it in 2 quarters. The position peaked at $173M in Q4 2024. 519 funds tracked by Wall St. Rank hold CRL as of Q2 2025.

  • Daniel Sundheim reported no remaining Charles River Laboratories position as of Q2 2025 after selling out during the quarter.
  • Daniel Sundheim sold 777,489 Charles River Laboratories shares in Q2 2025, an estimated $117M.
  • Daniel Sundheim first reported a position in Charles River Laboratories in Q4 2024 and held it in 2 quarters.
  • Daniel Sundheim's Charles River Laboratories position peaked at $173M in Q4 2024.
  • 519 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2025.

Based on D1 Capital Partners's 13F filing for Q2 2025, filed 14 Aug 2025.